Objective: The aim of the study was to identify risk factors for sexual dysfunction in BRCA mutation carriers who have undergone risk-reducing salpingo-oophorectomy (RRSO).
W omen who carry BRCA mutations have an increased lifetime risk of breast and ovarian cancer.
1,2 Risk-reducing salpingo-oophorectomy (RRSO) is recommended to BRCA1/2 mutation carriers by age 40 or after completion of childbearing, 3 and has been associated with significant reduction in ovarian, fallopian tube, peritoneal and breast cancer incidence, and improved survival. [4] [5] [6] Although survival benefit and cancer reduction from RRSO are clearly advantageous, the consequences of early surgical menopause are less well understood, especially regarding quality of life (QOL) concerns including sexual function. Decreased pleasure, frequency, and comfort during sexual activity have been noted in women who have undergone RRSO. [7] [8] [9] [10] Vaginal dryness, changes in sexual interest, and changes in sex life are among the most common menopausal symptoms after surgery; regrettably, many women report feeling that they received inadequate sexual counseling preoperatively. 11 As genetic testing for hereditary cancers gains wider utilization, and as more women are found to have BRCA mutations and recommended to undergo RRSO, the need for improved counseling about the impact of RRSO on sexual function is imperative in this unique population. Thus, our objective was to determine the prevalence of sexual dysfunction in BRCA1/2 carriers after RRSO and identify factors associated with sexual dysfunction after surgery. We hypothesized that concurrent depression and anxiety worsened sexual functioning after RRSO and that hormone therapy (HT) was associated with better sexual functioning.
MATERIALS AND METHODS Study participants
Known BRCA1 and/or BRCA2 mutation carriers were recruited from the Basser hereditary cancer risk clinics at the University of Pennsylvania through an in-person encounter or invitational letter. Participants were also recruited through a partnership with the Facing Our Risk of Cancer Empowered (FORCE) hereditary breast and ovarian cancer advocacy group. FORCE has an existing database of approximately 20,000 individuals interested in hereditary risk factors of breast and ovarian cancer who voluntarily receive information on a regular basis. Information about this study was posted in the FORCE monthly newsletter and on the FORCE website. Women interested in participation were directed to the Basser Center website, which contained full study details and contact information for study coordinators. Women who were 30 years old and over and who had or were planning to undergo RRSO during the enrollment period (March 2013-March 2014) were eligible for participation. The primary aim of this study was to examine risk factors for sexual dysfunction after RRSO. We included as a comparison group BRCA1/2 individuals who had not yet undergone surgery to isolate the effect of RRSO. Study participants provided informed consent and completed an online questionnaire comprising sociodemographic information (age, race, ethnicity, marital/domestic partnership status, education, and income level), medical diagnoses, medication usage, cancer history, and social history. Menstrual history, HT usage, fertility, and reproductive histories were also obtained. Validated survey instruments for quality of life indicators and sexual functioning were administered as part of the questionnaire. The University of Pennsylvania Institutional Review Board approved this study.
Instruments
The Female Sexual Function Index (FSFI) questionnaire was used to collect measures of sexual function overall and in six specific domains (Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain). 12 Test-retest reliability coefficients for each of the domains range from r ¼ 0.79 to 0.86 with a high degree of internal consistency (Cronbach's alpha values of >0.82). A total FSFI score of 26.55 is indicative of sexual dysfunction. 13 The Hospital Anxiety and Depression Scale (HADS) was used to assess clinically significant generalized anxiety and depression.
14 This validated questionnaire is divided into two subscales: one for anxiety (HADS-A) and depression (HADS-D), respectively. Score for each subscale (anxiety and depression) can range from 0 to 21 as follows: normal (0-7), borderline (8) (9) (10) , and abnormal or ''case'' (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
The Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality over a 1-month period. 15 A global score greater than 5 is indicative of poor sleep.
Statistical analysis
Chi-square, Student's t, Mann-Whitney U, and Fisher's exact tests were used as indicated to make between group comparisons of demographic characteristics, medical history, cancer history, surgical history, medication history, and quality of life measures (vasomotor symptoms, PSQI, HADS-A, and HADS-D). Initial comparisons were made between women who had completed an RRSO with those who had not yet undergone RRSO to isolate the role of oophorectomy in the BRCA1/2 positive population. Subsequent analyses focused on post-RRSO cohort to compare potential risk factors for sexual dysfunction between those who had sexual dysfunction (FSFI 26.55) versus those who did not (FSFI >26.55). To identify those participants with the most severe sexual dysfunction, we took the full distribution of women with an FSFI 26.55 and classified this group into quartiles. We performed a subanalysis of those who had the most severe sexual dysfunction as reflected by FSFI scores in the lowest quartile (FSFI summary score <14) and compared them with the women with sexual dysfunction in the upper quartiles. Multivariable logistic regression was used to identify risk factors for sexual dysfunction, including partner status, smoking, obesity, depression, anxiety, poor sleep, sex in the last year, cancer history, prior chemotherapy, prior mastectomy, history of hysterectomy, hot flashes, age at final salpingooophorectomy, HT, and psychiatric medication use. Ultimately, logistic models for sexual dysfunction were adjusted for age and obesity. Each covariate was fit one at a time, and variables were entered into the model if the P value was <0.1 in unadjusted analysis. Each FSFI domain (Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain) was examined separately to determine risk factors for the lowest domainspecific quartile scores. A subgroup analysis of women under the age of 50 with no history of cancer was performed to isolate the effect of somatic age on sexual function. A significance level of 0.0167 was used to account for multiple comparisons. Data were analyzed using STATA version 13 (College Station, TX).
RESULTS

Cohort characteristics
Of the 804 women surveyed, 87% (n ¼ 700) of participants were recruited from FORCE and the remainder from outpatient clinics. The majority (n ¼ 764) had undergone RRSO, whereas 40 had not yet undergone surgery at the time of survey (Fig. 1) . Table 1 describes the baseline characteristics of the cohort. Patients who had undergone RRSO (and completed the FSFI) were older at the time of survey completion (47.6 vs 35.7 y, P < 0.001), more likely to have a history of cancer, chemotherapy, prior hysterectomy, or have undergone prior mastectomy compared with those who had not undergone RRSO (P < 0.001 for all). RRSO was associated with a lower mean FSFI summary score overall (19.2 vs. 27.9, P < 0.001). If we consider age at the time of survey for the entire population, we found that age was significantly associated with an elevated odds of sexual dysfunction (odds SEXUAL DYSFUNCTION AFTER RRSO IN BRCA1/2 ratio [OR] 1.04, 95% CI, 1.02-1.07, P ¼ 0.001). Once we controlled for whether or not they had undergone RRSO, the association was, however, no longer significant (adjusted odds ratio [aOR] 1.03, 95% CI, 0.997-1.05, P ¼ 0.08). There was a higher percentage of patients with either case or borderline depression in the RRSO group (36.4% vs 11.4%, P ¼ 0.003) and the majority experienced hot flashes (65.6% vs 27.5%, P < 0.001).
Of those who did not complete the FSFI, 61 women did not answer any FSFI questions, an additional 100 women reported no sexual activity, and the remainder had skipped questions within the FSFI and thus did not have a FSFI summary score for analysis. The FSFI cannot be completed unless the participant is partnered, as there is at least one item that refers to a partner. Those who completed the FSFI were younger at the time of the survey (46.5 vs 50.2 y, P < 0.001) and at the time of RRSO (43.4 vs 46.9 y, P < 0.001), more likely to be married/in a domestic partnership (83.9% vs 63%, P < 0.001), to have had sex in the last year (89.2% vs 28.1%, P < 0.001), had a prior hysterectomy (55.6% vs. 44.3%, P ¼ 0.047), and less likely to have poor sleep (58.2% vs 72.3%, P ¼ 0.02).
Prevalence of and risk factors for sexual dysfunction
For the total cohort surveyed, patients who retained their ovaries were 60% less likely to experience sexual dysfunction as compared with those who had undergone RRSO (aOR 0.4, 95% CI, 0.2-0.9, P ¼ 0.02). Of those who underwent an RRSO, 409 (77.3%) women reported sexual dysfunction. When comparing those with and without sexual dysfunction, both groups were comparable with respect to premenopausal status at the time of RRSO (48.4% vs 49.2% P ¼ 0.67), age (46.8 vs 45.5 y, P ¼ 0.10), age at the time of RRSO (43.6 vs 42.5 y, P ¼ 0.15), current partner status (married or in domestic partnership-90.7% vs 85.8%, P ¼ 0.11), history of prior hysterectomy (53.5% vs 62.5%, P ¼ 0.09), and time elapsed 
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since surgery (3.5 vs 3.1 y, P ¼ 0.36) ( Table 2) . Compared with participants without sexual dysfunction, those with sexual dysfunction were more likely to have poor sleep (P ¼ 0.002), less likely to have had sex in the last year (P ¼ 0.005), more likely to have hot flashes (P ¼ 0.002), and less likely to be currently using systemic HT (P ¼ 0.002) or testosterone (P ¼ 0.02). Women with and without sexual dysfunction endorsed similar utilization of vaginal HT and nonhormonal therapies (including phytoestrogens, black cohosh, gabapentin, clonidine, primrose, or acupuncture) for hot flashes. Sexual dysfunction was associated with higher reporting of depression (P < 0.001) and anxiety (P ¼ 0.001). Utilization of psychiatric medications seemed to be higher in the group reporting sexual dysfunction (40.6% vs 30.8%) with borderline significance (P ¼ 0.054). The mean FSFI score was 20.3 for those with sexual dysfunction who did not score in the depression range and 19.8 for those with sexual dysfunction who did not score in the anxiety range. Participants with either hot flashes (aOR 1.92, 95% CI, 1.23-3.02) or depression (aOR 2.4, 95% CI, 1.4-4.1) had an approximately twofold greater risk of sexual dysfunction after adjusting for age at the time of survey, sexual activity in the last year, and psychiatric medication use.
To determine risk factors for those with the most severe sexual dysfunction in our cohort, we compared those with scores in the lowest quartile (FSFI 14) to those with sexual dysfunction in the upper quartiles (FSFI >14, 26.55), as well as with those without sexual dysfunction (FSFI >26.55) ( Table 3) . Women with scores in the lowest FSFI quartile were more likely to be obese (25.8% vs 17.4%, P ¼ 0.049) and have depression (50.3% vs 30.1%, P < 0.001) as compared with women with less severe sexual dysfunction. After adjusting for confounders (age at the time of survey, sex in the last year), depressive symptoms were significantly associated with the most severe sexual dysfunction (aOR 2.1, 95% CI, 1.3-3.5, P ¼ 0.002). Conversely, high educational attainment (college graduate or above) was associated with lower odds of experiencing the most severe sexual dysfunction (aOR 0.5, 95% CI, 0.3-0.9, P ¼ 0.013).
Those with severe sexual dysfunction were more likely to be older-both at the time of survey completion (mean age 47.6 vs 45.5 y, P ¼ 0.03) and at the time of RRSO (43.8 vs 42.5 y, P ¼ 0.03). Those with the worst sexual dysfunction were more likely to have poor sleep (P ¼ 0.04), less likely to have had sex in the last year (P < 0.001), more likely to have hot flashes (P ¼ 0.003), and less likely to be currently using systemic HT (P ¼ 0.002) or testosterone (P ¼ 0.03) compared with those without sexual dysfunction. They were also significantly more likely to report depression (<0.001) and anxiety (<0.001) symptoms as compared with those without sexual dysfunction, but psychiatric medication use was similar (P ¼ 0.06). 
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Sexual function domain analysis Each FSFI domain was analyzed separately (Table 4) to determine risk factors for psychological (Desire, Arousal, Satisfaction) versus physical aspects (Lubrication, Orgasm, Pain) of sexual dysfunction. Both depression (P < 0.001) and anxiety (P ¼ 0.03) were associated with low Desire scores, even after adjusting for sexual activity. Low Arousal was associated with age at the time of survey, obesity, and with depression; however, none of these risk factors remained significant after adjusting for sexual activity. Low Satisfaction was associated with depressive symptoms (aOR 1.7, 95% CI, 1.1-2.6, P ¼ 0.02). Current vaginal HT use was associated with improved Lubrication (aOR 0.3, 95% CI, 0.1-0.9, P ¼ 0.03) and Orgasm scores (aOR 0.2, 95% CI, 0.1-0.8, P ¼ 0.02).
Subgroup analysis
A restricted analysis of participants who were under the age of 50 with no history of cancer was performed to exclude the effect of somatic age and cancer therapies on sexual dysfunction. Consistent with findings from the total cohort, sexual dysfunction was associated with older age at the time of survey (42.5 AE 4.3 y, P ¼ 0.01), older age at RRSO (40.5 vs 38.9 y, P ¼ 0.01), and fewer participants who had sex in the last year (93% vs 100%, P ¼ 0.048) within this subgroup. Women under the age of 50 without cancer who had sexual dysfunction were more likely to have hot flashes (71.2% vs 46%, P ¼ 0.001), have poor sleep (98.2% vs 82.1%, P ¼ 0.003), and less likely to be using systemic HT (41.9% vs 66%, P ¼ 0.003). Depressive (P ¼ 0.001) and anxious (P ¼ 0.007) symptoms were both significantly associated with sexual dysfunction, as seen in the total RRSO cohort, with borderline significance with psychiatric medication use (39.3% vs 24.5%, P ¼ 0.05).
DISCUSSION
To our knowledge, this is the largest study to date to examine risk factors for sexual dysfunction in a cohort of BRCA mutation carriers after RRSO. The overwhelming majority of women who underwent RRSO reported sexual dysfunction (77.3%)-a finding that was both higher than BRCA carriers who had not pursued RRSO (36.7%) and general population prevalence estimates (40%). 16 In those who had undergone RRSO, our data suggest that although several factors contribute to sexual dysfunction, depression has the strongest and most consistent association, irrespective of antidepressant therapy. This association was independent of age, timing of most recent sexual activity, HT use, cancer history, and educational attainment, suggesting that depression is an important, potentially under-recognized and undertreated component in sexual function after RRSO.
Interestingly, the removal of the ovaries and loss of ovarian hormones seemed to have a significant negative effect on sexual dysfunction, as demonstrated by our comparison of sexual dysfunction in those who had undergone RRSO with those who had yet to undergo surgery. Although the data on the effects of premature surgical menopause on depressive symptoms are limited, some studies have found that surgically menopausal women have more depressive symptoms than those who were naturally menopausal. 17 A prospective study comparing 257 premenopausal women undergoing hysterectomy without oophorectomy with 57 women undergoing hysterectomy with oophorectomy demonstrated a higher rate of depressive symptoms in women with oophorectomy during a 3-year follow-up period. 18 Given the higher rate of depressive symptoms in women who had undergone RRSO as compared with those who had not yet undergone RRSO (13% vs 10%, P ¼ 0.003), it is certainly possible that premature surgical menopause might contribute to depression.
The relationship between depression and sexual dysfunction has been described as ''bi-directional.'' 19, 20 As such, it is often challenging to determine causality as depression may cause sexual dysfunction or vice versa, and treatment for one may improve or contribute to worsening symptoms of the other. Sexual dysfunction is highly prevalent among patients with depression. [21] [22] [23] One meta-analysis found that depression increased the risk of sexual dysfunction (OR 1.7, 95% CI, 1.1-2.8), and sexual dysfunction increased the risk of depression (OR 3.1, 95% CI, 1.7-5.9). 20 Furthermore, treatment of depression with certain antidepressants is associated with sexual dysfunction. 16, 24 In this study, although reported use of psychiatric medication use was high among those with sexual dysfunction (40.6%), use seemed to be a borderline risk factor for sexual dysfunction.
Our study also noted a reduction in sexual dysfunction among those taking HT after RRSO. HT after RRSO in premenopausal BRCA carriers without breast cancer is a viable treatment option for menopausal symptoms. 25, 26 Limited data exist on the safety of HT in this population; however, a recent systematic review from 2016 reported that the risks of subsequent cancer after HT are small. 27 In an observational study by Rebbeck et al, there was no elevated breast cancer risk with the use of HT after RRSO (hazard ratio 0.37, 95% CI, ¼ 0.14-0.96). 25 Given its benefits concerning menopausal symptoms, HT is not an unreasonable treatment option in BRCA carriers who have undergone prophylactic oohphorectomy. 27 There are mixed data regarding the benefit of HT on sexual dysfunction in this population. In a cross-sectional 
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study, HT reduced vasomotor symptoms in women post-RRSO, but did not improve sexual functioning. 28 Nonetheless, Finch et al demonstrated that HT use improved both symptoms of vaginal dryness and sexual discomfort among oophorectimized patients. 10 Several studies support the use of testosterone in addition to estrogen therapy for surgically menopausal women for improvement of sexual function and well-being. 29, 30 Although there was a reduced odds of sexual dysfunction associated with testosterone use in the present study (OR 0.3, 95% CI, 0.1-0.8), the overall number of participants who used testosterone in this study was small (n ¼ 14), so it is difficult to draw any substantial conclusions about the added benefit of testosterone.
HT has also been shown to reduce rates of depression and anxiety after bilateral oophorectomy in the non-BRCA population. 31, 32 This study showed no association between systemic HT use and depression or anxiety, although it may be underpowered to detect this association given the limited utilization of HT. If the increased rate of depressive symptoms was due to the loss of ovarian hormones, one would expect that HT would be associated with a reduced rate of these symptoms; however, this was not observed in this study. Due to the small percentage of women reporting HT use of any kind, we may not be able to draw strong associations between depression and HT. It is possible that if prevalence of HT use was higher, we might be able to observe the beneficial effect of these medications on depressive symptoms. As 24.6% of our participants who had undergone RRSO were using systemic HT, and HT was associated with a 50% risk reduction in sexual dysfunction, HT, however, may be an underutilized therapy that could confer substantial benefits.
We hypothesized that specific disorders of sexual function (ie, hypoactive sexual desire disorder, sexual arousal disorder, sexual pain disorders, and orgasmic disorders) would have unique risk factor associations. Depression seemed to have a negative impact on all aspects of sexual function, Desire, Arousal, Lubrication, Orgasm, Satisfaction and Pain, both physical and psychological. After adjusting for sexual activity in the last year, depression still associated with low Desire and Satisfaction and psychological aspects of sexual function. Obesity was associated with low Arousal, Lubrication, Orgasm, and Pain domain scores, both psychological and physical aspects of sexual function. This finding is consistent with published reports in obese populations [33] [34] [35] Our study also demonstrated a relationship between a history of cancer and Lubrication, Orgasm, and Pain, the physical aspects of sexual function which is consistent with previous studies that have demonstrated the negative impact that cancer diagnoses and treatments (chemotherapy, radiation, and surgery) have on sexual function. 36, 37 These findings strengthen an understanding of the facets of the sexual response that may be connected to modifiable risk factors.
Strengths and limitations
The major strengths of this study are its relatively large sample size and use of a validated female sexual dysfunction questionnaire. The BRCA mutation carrier population will be one of the most at-risk populations to undergo salpingooophorectomy, given what is known about the negative consequences of removing the ovaries, both in premenopausal and postmenopausal women. We used a novel approach to identify risk factors for the lowest FSFI scores, which would inform clinicians regarding who may be at risk for the worst sexual dysfunction. We also had available 40 BRCA mutation positive women who had yet to undergo RRSO and had the opportunity to compare FSFI scores before and after surgery, be it a small comparison group. This was a convenience sample recruited from an academic referral hospital for women with high-risk mutations and from a national website, these results may not be generalizable to all BRCA carriers; however, these findings are important to clinicians counseling patients who are presenting for RRSO consultation. Limitations of this study include its cross-sectional nature, thus causality cannot be determined. This study utilized self-reported patient surveys obtained through an online questionnaire, and not by a trained interviewer. Thus, quality of life symptoms such as depression and anxiety are self-reported and may not reflect clinically diagnosed disorders. Furthermore, the relationship between depression and sexual dysfunction is confounding and is difficult to completely disentangle. With regard to partner status, we were able to capture current relationship status (married or in a domestic partnership) through our questionnaire, however we did not obtain data on multiple partners or partner status before or after RRSO or after diagnosis of BRCA mutation. This would certainly be a consideration in prospective data collection. In addition, due to incomplete medication data, we were unable to report on specific dosing of HT or specific types of testosterone use. As there were 235 women who did not complete the FSFI portion, there may be selection bias with respect to the women who chose to answer these questions. As our analysis demonstrated, the women who completed the FSFI were, however, overall similar to the women who did not. Although the study is cross-sectional in nature, the size of cohort and ability to analyze subgroups allowed for evaluation of sexual dysfunction. A prospective longitudinal study following sexual functioning before and after surgery would be the ideal next step to understanding the role of surgery on sexual dysfunction. We are currently following the 40 women who had yet to undergo surgery in this study to compare their presurgery and postsurgery scores.
CONCLUSIONS
Sexual dysfunction is highly prevalent in women with BRCA mutations after RRSO. Depression is a significant risk factor for sexual dysfunction and may be both underrecognized and/or undertreated. Any provider, in oncology, gynecology, or primary care, should be highly vigilant about assessing both sexual dysfunction and depression in women who have had their ovaries removed. As HT has not been associated with negative long-term consequences in this population (albeit with limited data), HT may be of benefit CHAN ET AL in the management of sexual dysfunction and should be considered in those women without breast cancer. Educating women about the possible sexual side effects of surgical risk reduction is imperative and addressing sexual dysfunction and its risk factors is paramount to improving quality of life after RRSO in patients with BRCA mutations.
